FDA approves fitusiran for hemophilia A, B patients aged 12 years and up

Published Date: 11 Apr 2025

Fitusiran is administered subcutaneously starting once every 2 months for patients aged 12 years and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer

2.

Pediatric high-grade gliomas: Research reveals effective targeting with avapritinib

3.

In prostate cancer survivorship, sleep disturbances are underappreciated.

4.

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

5.

a cutting-edge cancer diagnostic tool.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot